Pr. Dr. Didem Karaçetin

A.2 Yılmaz O B, Karacetin D, Kabukcuoglu F, Taskin T , Yener S (2011). Immunohistochemical study of E-cadherin and ?-catenin expression in colorectal carcinomas. Pol J Pathol , 62(1), 19-24

A.3 Karacetin D, Cakir A, Agaoglu F, Çamlıca H , Ergen A, Dizdar Y, Darendeliler E (2010). Dose distribution in 3-dimensional conformal radiotherapy for prostate cancer: comparison of femur doses for four treatment techniques. Journal of Radiotherapy in Practice , 41-51

A.4 Baycan D, Karacetin D, Balkanay A, Barut Y (2012). Field-in-field IMRT versus 3D-CRT of the breast. Cardiac vessels, ipsilateral lung, and contralateral breast absorbed doses in patients with left- sided lumpectomy: a dosimetric comparison. Jpn J Radiol, Doi: 10.1007/s11604-012-0126

A.5 Karacetin D, Okten B, Yalcin B, Incekara O (2011). Concomitant temozolomide and radiotherapy versus radiotherapy alone for treatment of newly diagnosed glioblastoma multiforme. Journal of Buon, 133-137.

A.6 Ozdemır C, Karacetın D, Tuna S, Karadeniz A (2011). Treatment and clinicopathologic predictors for adenoid cystic carcinomas of the head and neck. Journal of BUON, 123-126.

A.7 Karacetin Didem, Cakir Aydın, Karaman Sule, Kemikler Ebru , Tenekeci Nuri , Saglam Esra , Oral Ethem, Kizir Ahmet (2012). Critical Normal Structures Doses for Non Small Cell Lung Cancer using 3-D Conformal Radiotherapy. J Nucl Med Radiat Therapy, Doi: 10.4172/2155-9619.1000128

A.8 C Kulucan, R U Gursu, C Muderrısoglu, N Dursun, D Karaçetin (2014). A Case of Gastric Carcinoma with Breast Metastasis. International Journal of Hematology and Oncology, 22(3), 211-212.

A.9 Güner S , Karaçetin D, Yüksel M (2013). Primary Testicular Diffuse Large B-Cell Lymphoma: ACase Report. World Journal of Oncology , 4(1), 61-65.

A.10 Karacetin D, Incekara O (2006). Gemcitabine-cisplatin given on day 1 every 3 weeks in advanced non-small cell lung cancer. Journal of BUON, 181-184.

A.11 Karacetin D, Yucel B, Leblebicioglu B, Aksakal O, Maral O, Incekara O (2004). A randomized trial of amifostine as radioprotector in the radiotherapy of head and neck cancer. Journal Of BUON, 23- 26.

A.12 Karacetın D, Incekara O (2004). A randomized trial of 5-fluorouracil, leucovorin, cisplatin and epirubicin (PELF) versus 5-fluorouracil, leucovorin and etoposide (ELF) given as adjuvant chemotherapy to patients with resected advanced gastric adenocarcinomas. Journal Of BUON,263- 267.

A.13 Karaçetin D, Kızılkaya O, Uyanoglu A, Maral O, Incekara O (2001). Bilateral Amaurosis during systemic chemotherapy with cisplatin. Jjournal Of BUON, 323-325.

A.14 Karaçetin D, Alkan Ç Z, Yigit Ö, Azızlı E Balkanay AY , Celık G , Baycan D (2013). Effects of oral glutamin on radiation induced laryngeal mucosal damage. Head Neck Oncology, 15(4), 37

A.15 Nazlı E. T. Özden , F. Behice Cinemre , Hakan Cinemre , Selim Öğüt, Nurten Bahtiyar , Didem Karaçetin, Haldun Şükrü Erkal , Birsen Aydemir . The Infl uence of Radiotherapy on Circulating Mirna Expression Levels and Hemorheological Properties in Prostate Cancer. J hum rhythm – March 2017;3(1):42-49

A16. Didem Karacetin, Mehmet Ali Nazlı, Didem Can Trabulus, Canan Kelten and Yesim Karagoz. with High-Resolution Ultrasonography of Skin Toxicity due to Radiotherapy in Patients with Breast Cancer. Archives in Cancer Research, 2016; Vol.4 No.3:90

A17. Can Trabulus D, Altinsoy E, Karacetin D, Nazli MA, Kelten Talu C. Preventive role of superoxide dismutase on radiation-induced periprosthetic capsule development.J Surg Res. 2018 Nov;231:30-35. doi: 10.1016/j.jss.2018.04.055.

A18. Tatar G, Cermik TF, Karagoz Y, Gundogan C, Karacetin D, Yildiz E, Yigit O.The value of whole- body contrast-enhanced 18F-FDG PET/CT imaging in the diagnosis and staging of patients with laryngeal carcinoma. Nucl Med Commun. 2018 Apr;39(4):334-342.

A19. Didem Karaçetin, Şebnem İzmir Güner and Özden Özer. Autoimmune Hemolytic Anemia Preceding the Diagnosis of Hodgkin’s Disease: a Case Report and Review of the Literature. JOJ Case Stud 4(4)JOJCS.MS.ID.555642, 2017

A20. Didem Karacetin , Duygu Baycan, M Ali Nazli, D Can Trabulus, M Emin Gunes and Yücel Barut. Dosimetric Comparison of Dynamic IMRT, Field-in-Field IMRT and 3D-CRT in Left-Sided Breast Cancer after Breast-Conserving Surgery. ACTA Scientif Cancer Biology.Volume 2 Issue 5 July 2018

A21. Sebnem Izmir Guner, Didem Karacetin and Ekrem Guner. Immunoglobulin D Multiple Myeloma-A Rare Case. J Clin Case Rep 5: 618. 2015

A22. Gulsen Pinar Soydemir, Nazli Bilici, Elif Eda Tiken, Ayben Yentek Balkanay, Ali Firat Sisman,Didem Karacetin. Hippocampal sparing for brain tumor radiotherapy: A retrospective studycomparing intensity-modulated radiotherapy and volumetric-modulated arc therapy. Journal ofCancer Research and Therapeutics. DOI: 10.4103/jcrt.JCRT-32-19, 2020

A23. Karaçetin D, Hale A, Didem CT, Cigdem UA, Canan K, Cihan O, Murat U and Selim A. AMH-BreastCancer, Letter to the Editor. Journal of Gynecological Oncology, 2019 | Volume 2 | Issue 4 | Article10211

A24.Canan Kelten, Ceren Boyacı, Cem Leblebici, Didem Trabulus, Mehmet A. Nazlı, Didem Karaçetin,Umar R. Gürsu. Cystic Hypersecretory Ductal Carcinoma Of The Breast Mimicking Mastitis.Letter toEditör. Breast Case, 2015;4(1):1-3

A25.Hüsniye Isin, Emre özgür, Canan Kelten Talu, Didem Can Trabulus, Didem karacetin, Ugur Gezer.Impact of histone methyltransferase SUV420H2 in breast cancer. DOI: 10.3892/br.2020.1336

A26. Afsar CU, Aral H, Can O, Can TD, Karacetin D, Ali NM, Umar GR, Karabulut S..Serum fetuin-A andRANKL levels in patients with early stage breast cancer.J Med Biochem. 2023 Mar 15;42(2):249-257

A27. Keskin M, Kompuinen J, Harmankaya İ, Karaçetin D, Nissilä V, Gürsoy M, Sorsa T, Gürsoy UK.OralCavity Calprotectin and Lactoferrin Levels in Relation to Radiotherapy.Curr Issues Mol Biol. 2022 Sep26;44(10):4439-4446.

A28. Can S, Atilla Ö, Karaçetin D.Calculated and measured radiation dose for the low energy xoft axxent eBT X-ray source. BMC Res Notes. 2023 Feb 28;16(1):25.

A29. Brandt E, Keskin M, Tervahartiala T, Yılmaz M, Harmankaya İ, Karaçetin D, İpek T, Gürsoy UK,Rautava J, Gupta S, Hagström J, Räisänen IT, Sorsa T. Radiotherapy Increases aMMP-8-Levels andNeutrophil/Lymphocyte Ratio Rapidly in Head and Neck Cancer Patients: A Pilot Study.CancerControl. 2023 Jan-Dec;30:10732748231163653.

A30. Brandt E, Keskin M, Tervahartiala T, Yılmaz M, Harmankaya İ, Karaçetin D, İpek T, KahramanGürsoy U, Gupta S, Räisänen IT, Hagström J, Rautava J, Sorsa T.Radiotherapy Increases aMMP-8-Levels and Neutrophil/Lymphocyte Ratio Rapidly in Head and Neck Cancer Patients: A Pilot Study.Cancer Control. 2023 Jan-Dec;30:10732748231187282

B. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında basılan bildiriler

B.1 Karaçetin Didem, Maral Özlem, Aksakal Öznur, Okten b, Yalcın B, Incekara O, (2007).Gemcitabineand docetaxel combination regimen in metastatic breast cancer. ASCO AnnualMeeting konferansı,

B.2 Yılmaz Banu, Saygılı Gamze, Kabukçuoglu Fevziye, Karaçetin Didem Prognostic importance of Cox-2 expression in patients with colorectal cancer. Esmo Conference: 11 th World CongressBarcelona-Spain, 2009 (Poster)

B.3 Karaçetin Didem, Kemikler Ebru, Karaman Sule, Cakır A, Tenekeci N , KaytanSaglam E , Oral EN ,Kizir A, Crictical normal tissues dose for non small cell lung. ESTRO 27konferansı Göteborg-Sweden2008 (Poster)

B.4 Karaçetin Didem, Çakır Aydın, Agaoglu Fulya, Camlıca H, Ergen ,A Dizdar Y,Darendeliler E Dosedistribution in 3-dimensional conformal radiotherapy for prostate cancer:comparison of femur dosesfor four treatment techniques". ESTRO Göteborg-Sweden, 2008(Poster)

B.5 Karaçetin Didem, Ökten Begüm, Maral Özlem, Incekara O, Aslan M , Aykanat, A

Inductionchemotherapy followed by concomitant chemoradiotherapy in local advanced head andneckcancer. 33rd ESMO Congress Stockholm, Sweden, 2008 (Poster)

B.6Karaçetin Didem, Ökten Begüm, Maral Özlem, Incekara Oktay "Concomitant chemoradiotherapyand then sequential temozolomide in patients with glioblastome multiforme. 18th Internationalcongress on anticancer treatment Paris- France, 2007 (Poster)

B.7 Karaçetin Didem, Maral Özlem, Yalçın Berrin, Incekara O Capacitabine and Oxaliplatin ( XELOX) AsFirst Line Treatment For Patients With Metastatic colorectal cancer p:170 pp.,. WorldCongress onGastrointestinal Cancer Barcelona- Spain, 2006 (Poster)

B.8 Karaçetin Didem, Incekara Oktay (2004). Gemcitabine-Cisplatin given D1 and every 3 weeks inadvanced non small cell lung cancer ", p734. 29th ESMO Congress Vienna- Austria (Poster)

B.9 Tatar G, Çermik TF, Karagöz Y, Yigit Ö, Karaçetin D, Gündogan C, Yıldız E, Hamit B, Yılmaz M(2014). Role of contrast enhanced ( dual phase) 18- F PET CT in the diagnosis and initial stagingof thewith larengeal carcinoma. 2. EANM Congress (Sözlü Bildiri)

B.10 Kelten C, Boyacı C, Leblebici C, Behzatoglu K, Can Trabulus D, Nazlı MA, Gürsu RU, KaraçetinD,Bozkurt E (2014). A Malignant Philloides Tumour of aneuriysmal bone cyst-like areas in pregnancy.

PS 03-011. 26. European Congress of Pathology (Poster)

B.11 Kelten C, Boyacı C, Gürsu RU, Aksoy S, Trabulus D, Karaçetin D, Sirin S (2014).Clinicopathologicalanalysis of patients with triple negative breast cancer PS 03-132. 26.European Congress of Pathology

B.12 Kelten C, Boyacı C, Trabulus D, Aksoy S,Gürsu RU, Karaçetin D, Sirin S, Nazlı MA, Bozkurt E(2014). Clinicopathological analyse of patient with breast cancer from a single center in Turkey.PS03-152. 26. European Congress of Pathology (Poster)

B13. Dalay M. N., ,Karaçetın Dıdem,Canan Kelten, Trabulus Didem. Methilation Of The Wrn, Dok1And DSP Genes In Breast Cancer. Epigenetics and Cancer, 2015 Keystone Symposia.USA

B14. Selim Öğüt, Birsen Aydemir , F. Behice Cinemre, Hakan Cinemre. , DidemKaraçetin, HaldunŞükrü Erkal, Yağmur Karakoç ;miRNA-521 expression levels and manganese superoxide dismutaseactivities to response ionizing radiation in patients with prostate cancer. 6th World Congress ofOxidative Stress, 24 – 27 May 2016 Calcium Signaling and TRP Channels

B15. Selim Öğüt, Birsen Aydemir, F. Behice Cinemre, Hakan Cinemre , Nazlı Eyvan Topçu,DidemKaraçetin, Haldun Şükrü Erkal, Manganese superoxide dismutase activities and circulating levels ofzinc, magnesium, calcium, iron in patients with prostate cancer before and after radiation therapy516 6th World Congress of Oxidative Stress, 24 – 27 May 2016 CalciumSignaling and TRP Channels

B16. Selim Öğüt, Birsen Aydemir, F. Behice Cinemre, Hakan Cinemre,Didem Karaçetin, Haldun Şükrü, Circulating Activitıes of Manganese Superoxide Dismutase in Patients With Prostate CancerBefore and After Radiotherapy, 11th International Conference on Protein Stabilisation May 09-11,2016 Istanbul Military Museum – Istanbul, Turkey

B17. Selim Öğüt, Birsen Aydemir, F. Behice Cinemre, Hakan Cinnemr, Didem Karaçetin, Haldun ŞükrüErkal, Circulatıng Levels of Apoptotic Markers and P53 in Patients With Prostate Cancer Before andAfter Radiotherapy, 11th International Conference on Protein Stabilisation May 09-11, 2016 IstanbulMilitary Museum – Istanbul, Turkey

B.18 Selim ÖĞÜT1,2, F. Behice Cınemre3 , Hakan Cinemre4 , Didem Karaçetin2,5 , Birsen Aydemır1Cırculatıng Levels Of Cytochrome C, Caspase 3, Caspase 9 And P53 In Patıents Wıth Prostate CancerBefore And After Radıotherapy”. Turkısh Physıcal Socıety 33rd Internatıonal PhysıcsCongress,Bodrum, Muğla, 6-10 Sep 2017

B19. Öğüt S, Aydemir B, Cinemre FB, Cinemre H, Karaçetin D. “The role of apoptotic markers inpatients with prostate cancer radiotherapy” PP-26, Istanbul University 2nd World Conference onTechnology, Innovation and Entrepreneurship, Istanbul Congress Center, Istanbul, 12-14 May 2017.

B20. Isın Mustafa,Isın Hüsniye,Talu Canan Kelten,Trabulus Didem,Karaçetin Didem,Dalay NejatInvolvment of miRNA29b in breast cancer. MicroRNAs and Noncoding RNAs in Cance KeystoneSymposia, USA 2015 49.

B21. Selim ÖĞÜT F. Behice SERİNKAN CiNEMRE, Nurten BAHTiYAR , Hakan CİNEMRE ,DidemKARAÇETİN , Birsen AYDEMİR “The Effects of Radiotherapy on Total Antioxidant Capacity and 8-Hydroxy-2'-Deoxyguanosine Levels in Prostate Cancer Trakya University Association of ThraceUniversities 1st International Health Sciences Congress, Trakya University Balkan Campus, 23-25November 2017

B22. Aral H, Karaçetin D, Özer C, Can Trablus D, Usta M. Changes in fertility hormone levels duringanti-cancer therapy in breast cancer. EuroMedLab Paris 2015, 21st European Congress onClinical Chemistry & Laboratory Medicine. June 21-25, 2015, Paris. Clin Chem Lab Med 2015;53, Special Suppl, pp S178.

B23. Aksoy T, Aral H, Can Trablus D, Serin E, Kelten C, Usta M, Aksoy Ş, Karaçetin D.Serumadiponectin levels and histopathological CerbB2 immunostaining pattern in breast cancer.Paris 2015, 21st European Congress on Clinical Chemistry & amp; Laboratory Medicine.June 21-25, 2015, Paris. Clin Chem Lab Med 2015; 53, Special Suppl, pp S397.

B24. Aral H, Özer C, Koro A, Karaçetin D, Usta M, Orhan B, Gürsu RU, Bektaş H, Serin E. Serumphospholipase A2 levels measured by flourometric method in colon cancer, 2 nd Middle EastMolecular Biology Society (MEMBS) 17-20 September, 2015, İstanbul.

B25.Özer C, Aral H, Karaçetin D, Gürsu RU, Can Trablus D, Bektaş H, Usta M, Serin E, Güvenen G. Therelationship between serum 25-hydroxy vitamin D levels and insulin resistance in breast and coloncancer. EuroMedLab Paris 2015, 21st European Congres on Clinical Chemistry & LaboratoryMedicine. June 21-25, 2015, Paris. Clin Chem Lab Med 2015; 53, Special Suppl, pp S403.

B26. Selim Öğüt, F. Behice Cinemre , Nurten Bahtiyar , Hakan Cinemre , Didem Karaçet BirsenAydemir. The effects of Radiotherapy on P53, Zinc and Coopper levels in patients with prostatecancer. Trakya University Association of Thrace Universities 1st International Health SciencesCongress, Trakya University Balkan Campus, 23-25 November 2017,OP-67

C. Kitap ve Kitapta yazılan bölümler

C1. Barut A.Y, Çermik F, Karaçetin D. Radyasyon Güvenliği El Kitabı. İstanbul, S.B. İstanbul Eğitim VeAraştırma Hastanesi Yayınları, 2011. "RADYASYON SAĞLIĞI VE RADYASYONDAN KORUNMA"

C2. Mehmet Ali Nazlı, Didem Karaçetin, Burçak Yılmaz; Radyasyon Güvenliği El Kitabı.BaşakşehirÇam ve Sakura Şehir İstanbul, S.B. Yayınları

C3. Her Yönüyle Prostat Kanseri. Prostat Kanserinde Radyoterapi, Akademisyen yayınevi,2023

D. Ulusal hakemli dergilerde yayımlanan makaleler :

D.1. Ekrem Güner, Özdem Levent Özdal, Emre Şam, Ayben Yentek Balkanay, Şenol Tonyalı, Halil FıratBaytekin,Didem Karaçetin. Nadir bir olgu: Retroperitoneal liposarkom .A rare case: Retroperitonealliposarcoma. Yeni Üroloji Dergisi – The New Journal of Urology 2018; 13 (3): 74-77

D.2. Inanç K, Maral Ö, Karaçetin D, Uyanoglu A, Incekara O (2000). Nazofarenks Kanserinde TedaviYaklasımımız ve Sonuçlarımız.. Sisli Etfal Hastanesi Tıp Bülteni , 19-22.

D.3 Maral Ö, Karaçetin D, Peksu S, Uyanoglu A , Aksakal A, Incekara O (2000). Küçük HücreliAkciger Kanserli Hastaların Genel Özellikleri. Sisli Etfal Hastanesi Tıp Bülteni., 34-36.

D.4 Karaçetin D, Kızılkaya O, Sensöz S, Uyanoglu A, Incekara O (1996). Meme Kanserinde AtipikMetastaz Yeri Olarak Tükrük Bezi tutulumu. Anadolu Tıp Dergisi, 10-12.

D.5 Uyanoglu A, Karaçetin D, Maral Ö, Aksakal Ö, Incekara O (2000). Low Grade AstrositomalıHastaların Genel Özellikleri. Sisli Etfal Hastanesi Tıp Bülteni, 34-36.

D.6 Uyanoglu A, Maral Ö, Karaçetin D, Aksakal Ö, Incekara O (2000). Low Grade AstrositomalıVakalarda Lokal Radyoterapi. Sisli Etfal Hastanesi Tıp Bülteni

D.7 Aksakal Ö, Kızılkaya O, Zekai H, Korkmaz Karaçetin D, Özgen Z, Incekara O (1996). Bir OlguNedeniyle Rhabdomyosarkom. Anadolu Tıp Dergisi, 45-47.

D.8 Maral Ö, Karaçetin D, Peksu S, Uyanoglu A, Aksakal Ö, Incekara O (2000). Küçük HücreliAkciger Kanserinde Tedavi Sonuçlarımız. Sisli Etfal Hastanesi Tıp Bülteni , 34-36.

D.9 KIzılkaya O, Yücel B, Karaçetin d, Incekara O (2000). Non-Hodgkin Lenfoma Tedavi Sonuçları. SisliEtfal Hastanesi Tıp Bülteni, 32-34.

D.10 Karaçetin D, Maral Ö, Ökten B, Kabukçuoglu F, Incekara o (2007). Orbital liposarkom: Olgusunumu. Türk Onkoloji Dergisi , 183-185.

D.11 Maral Ö, Karaçetin D, Aksakal Ö, Incekara O (2007). Primer Prostat Lenfoması. Sisli EtfalHastanesi Tıp Bülteni , 49-51.

D.12 Kökpınar S, Toklu A, Karaçetin D (2006). Yumusak doku Radyonekrozunda Hiperbarik OksijenTedavisi. Türk Onkoloji Dergisi , 47-51.

D.13 Karaçetin D, Maral Ö, Ökten B, Aksakal Ö, Incekara O (2005). Serviks Kanserli HastalardaPrognostik Faktörler. Sisli Etfal Hastanesi Tıp Dergisi , 13-16.

D.14 Karaçetin D, Baser Y, Aksakal Ö, Maral Ö, Yüce Bl, Özcan D, Incekara O (2004). Evre IVepitelyal over kanserli hastalarda cisplatin- taxol kombinasyonu ile toksisite ve sagkalımındegerlendirilmesi. Sisli Etfal Hastanesi Tıp Bülteni , 19-21.

D.15 Karaçetin D, Özcan D, Maral Ö, Aksakal Ö, Yücel B, Baser Y , Incekara O (2004). EndometriumKanserlerinde AdjuvanRadyoterapi Sonuçlarımız ve Prognostik Faktörler. Sisli Etfal Hastanesi TıpBülteni , 22-24.

D.16 Maral ö, Karaçetin D, Yücel B, Aksakal Ö, Özcan D, Baser Y , incekara O (2003). Non Small CellAkciger Kanserinde Kemoterapi Protokollerinin Karsılastırılması. Sisli Etfal Hastanesi Tıp Bülteni 23-25.

D.17 Peksu S, Karaçetin D, Maral Ö, Mayadaglı A, Incekara O (2002). Supraglottik LarenksKanserlerinde Postoperatif Radyoterapinin Rolü ve Sonuçları. Sisli Etfal Hastanesi Tıp Bülteni , 50-52

D.18 Karacetin D, Okten B, Yalcin B, Incekara O (2010). Prognostıc factors for glioblastomamultiforme (GBM) treated wıth radıotherapy alone versus radıotherapy plus concomıtant andadjuvant temozolomıde. J. Med. Med. Sci, 280-285.

D.19 Karaçetin D, Kızılkaya O, Mayadaglı A, Incekara O (2000). Meme Kanserinde TedaviSonuçlarımız. Sisli Etfal Hastanesi Tıp Bülteni , 53-56.

D.20 Karaçetin Didem (2000). 327 Meme Kanserli Hastanın Retrospektif Analizi. Sisli Etfal HastanesiTıp Bülteni , 34-36.

D.21 Uyanoglu A, Karaçetin D, Maral Ö, Inanç K, Incekara O (2000). Küçük Hücre Dısı AkcigerKanserinde Tedavi Sonuçlarımız. Sisli Etfal Hastanesi Tıp Bülteni , 43-46.

D.22 Karaçetin D, Kızılkaya O, Yücel B, Incekara O (2000). TestisTümörlü Olgularımız. Sisli EtfalHastanesi Tıp Bülteni , 34-36.

D.23 Maral Ö, Inanç K, Karaçetin D, Uyanoglu A, Incekara O (2000). Akciger Kanserli Hastalarda UzakMetastaz.. Sisli Etfal Hastanesi Tıp Bülteni , 24-26.

D.24 Gürsu R U, Kesmezacar Ö, Karaçetin D, Mermut Ö, Ökten B, Güner S I (2012). Yeni kurulan birÜnitenin 18 aylık sonuçları. Istanbul Tıp Dergisi, 13-18., Doi: 10.5505/1304.8503.2012.55264

D.25 Karaçetin D, Koçar H, Maral Ö, Öztürk Ö, Yalçın B, Incekara O (2009). Postmastektomi AdjuvanRadyoterapi Alan Meme Kanserli Hastalar. Istanbul Tıp Dergisi, 20-23.

D.26 Yalçın B, Karaçetin D, Ökten B, Incekara O (2009). Lokal ileriEvre Serviks Kanserinde Tek BasınaRadyoterapi ile Haftalık Sisplatin ile eszamanlı radyoterapi uygulamasının karsılastırılması.Istanbul TıpDergisi, 174-180.

D.27 Tuna S, Karaçetin D, Basaran M, Agaoglu F, Dogan O , Buyukbabani N (2009). Conjunctival MaltLymphoma. Istanbul Tıp Derrgisi, 198-201.

D.29 Yücel B, Karaçetin D, Kızılkaya O, Incekara I (2000). Hodgkin Lenfomalı HastalardaTedaviSonuçlarımız. Sisli Etfal Hastanesi Tıp Bülteni, 20-22.

D30. Ayben Yentek Balkanay, Didem Karaçetin, Ekrem Güner. Prostat Karsinomunda RadikalProstatektomi Sonrası Adjuvan Radyoterapi: Erken Dönem Klinik Sonuçlarımız. J Reconstr Urol2018;8(1):6-10